NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization129.56 mln
Float11.03 mln
Earnings Date05/14/2026
Piotroski F-Score
5
/ 9
Neutral
1-Year Forecast
16.00
Transformational upside
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-49.63
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Alpha Cognition Inc. is a drug development company based in Vancouver, Canada, focused on finding new ways to treat brain and nervous system diseases across North America. Its lead product, ZUNVEYL, is an approved oral medication for Alzheimer's disease, with ongoing research exploring its use alongside other treatments for more advanced stages of the condition. The company is also working on several early-stage programs targeting conditions such as traumatic brain injury, acute pancreatitis, and rare diseases that affect muscle and nerve function.
